Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells

Breast cancer can be classified into molecular subtypes. Tumors overexpressing HER2 protein are more aggressive and metastatic; hence, patients have a poor prognosis. Anti-HER2 strategies, such as the monoclonal antibody Trastuzumab (Tz), have therefore been developed. Despite this progress, not all...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncotarget
Hoofdauteurs: Vanderhoeven, Fiorella, Redondo, Analía Lourdes, Martinez, Ana Laura, Vargas-Roig, Laura María, Sanchez, Angel Matias, Flamini, Marina Inés
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Impact Journals LLC 2018
Onderwerpen:
Research Paper
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5995169/
https://ncbi.nlm.nih.gov/pubmed/29899874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25480
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items